Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine

– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo –

CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based candidates as a new class of medicines, today announced new preclinical data from its pan beta-coronavirus vaccine program, which aims to protect against all SARS-CoV-2 variants of concern and potential future strains belonging to the beta-coronavirus family. The data, which are being presented today at the World Vaccine Congress 2022 in Washington, D.C., demonstrate the potential for a novel engineered exosome-based vaccine candidate derived from Codiak’s exoVACC™ platform to induce cross-neutralizing antibody protection against multiple strains of coronaviruses and an antigen-specific and comprehensive immune response against structurally conserved regions of multiple coronavirus variants.